Orocidin and Bio-Convert expects to begin pilot efficacy studies in 2025
Go back to Orocidin and Bio-Convert expects to begin pilot efficacy studies in 2025| AdvanSource Biomaterials Corpration (AMEX: ASNB) | Delayed: 0.85 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.85 | 52 Week High | $0.41 | |||
| Open | $7.87 | 52 Week Low | $0.05 | |||
| Day High | $0.85 | P/E | N/A | |||
| Day Low | $0.85 | EPS | $-0.12 | |||
| Volume | 80 | |||||
| NORD ANGLIA EDUCATION, Inc. (AMEX: NORD) | Delayed: 3.50 -0.52 (12.94%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.02 | 52 Week High | $23.88 | |||
| Open | $3.60 | 52 Week Low | $14.58 | |||
| Day High | $3.60 | P/E | N/A | |||
| Day Low | $3.49 | EPS | $0.00 | |||
| Volume | 8,185 | |||||



